This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ferrell, M. et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat. Med. 30, 424–434 (2024).
Guyton, J. R. & Boden, W. E. Niacin, food intake and cardiovascular effects. Nat. Med., in press (2024).
Schreiber, S., Waetzig, G. H., Laudes, M. & Rosenstiel, P. Cardiovascular safety of vitamin B3 administration. Nat. Med., in press (2024).
Jenkins, D. J. A. et al. Supplemental vitamins and minerals for CVD prevention and treatment. J. Am. Coll. Cardiol. 71, 2570–2584 (2018).
Shibata, K., Shimada, H. & Taguchi, H. Fate of nicotinamide differs due to an intake of nicotinamide. Biosci. Biotechnol. Biochem. 60, 1204–1206 (1996).
Fulgoni, V. L. 3rd, Keast, D. R., Bailey, R. L. & Dwyer, J. Foods, fortificants, and supplements: where do Americans get their nutrients? J. Nutr. 141, 1847–1854 (2011).
Wu, B. J. et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30, 968–975 (2010).
Perlzweig, W. A., Rosen, F., Pearson, P. B., Peck, B. J. & Sparks, P. Comparative studies in niacin metabolism. The fate of niacin in man, rat, dog, pig, rabbit, guinea pig, goat, sheep and calf. J. Nutr. 40, 453–469 (1950).
Felsted, R. L. & Chaykin, S. N1-methylnicotinamide oxidation in a number of mammals. J. Biol. Chem. 242, 1274–1279 (1967).
Yoshimura, N. et al. N-methyl-2-pyridone-5-carboxamide (N-Me-2PY) has potent anti-fibrotic and anti-inflammatory activity in a fibrotic kidney model: is it an old uremic toxin? Clin. Exp. Nephrol. 27, 901–911 (2023).
Author information
Authors and Affiliations
Contributions
All authors participated in the initial writing and subsequent editing and review of this response.
Corresponding author
Ethics declarations
Competing interests
S.L.H. reports being named as a co-inventor on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. S.L.H. also reports having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab, a fully owned subsidiary of Quest Diagnostics, and Procter & Gamble. S.L.H. is a paid consultant for Zehna Therapeutics and Proctor & Gamble, and has received research funding from Zehna Therapeutics, Proctor & Gamble, Pfizer and Roche Diagnostics. W.H.W.T. has served as a consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, WhiteSwell, Boston Scientific, CardiaTec Biosciences, Intellia Therapeutics, Bristol Myers Squibb, Alleviant Medical, Alexion Pharmaceuticals, Salubris Biotherapeutics and BioCardia, and has received honoraria from Springer, Belvoir Media Group and the American Board of Internal Medicine. All other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tang, W.H.W., DiDonato, J.A., Allayee, H. et al. Reply to Guyton, J. R. & Boden, W. E.; Schreiber, S. et al.. Nat Med 30, 2448–2449 (2024). https://doi.org/10.1038/s41591-024-03222-0
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41591-024-03222-0